Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report
May 05
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 07, 2025
DataAggregated Company Financials
Companies566
- 7D-6.3%
- 3M-15.0%
- 1Y-14.1%
- YTD-9.0%
Over the last 7 days, the Biotech industry has dropped 6.3%, driven by a pullback from Vertex Pharmaceuticals of 11%. The industry has fallen 14% in the last year. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 07 May 2025 | US$949.3b | US$154.1b | -US$25,408,936,426.34 | 18.3x | -37.4x | 6.2x |
| Fri, 04 Apr 2025 | US$791.2b | US$118.6b | -US$37,117,653,368.22 | 21.5x | -21.3x | 6.7x |
| Sun, 02 Mar 2025 | US$850.7b | US$118.9b | -US$37,265,127,499.97 | 17x | -22.8x | 7.2x |
| Tue, 28 Jan 2025 | US$983.3b | US$149.5b | -US$26,320,225,889.85 | 17.1x | -37.4x | 6.6x |
| Thu, 26 Dec 2024 | US$990.4b | US$149.9b | -US$26,369,148,329.00 | 16x | -37.6x | 6.6x |
| Sat, 23 Nov 2024 | US$1.0t | US$150.0b | -US$26,559,949,256.44 | 17x | -37.7x | 6.7x |
| Mon, 21 Oct 2024 | US$908.0b | US$113.1b | -US$35,950,283,773.02 | 21.7x | -25.3x | 8x |
| Wed, 18 Sep 2024 | US$929.9b | US$113.2b | -US$35,966,527,614.94 | 22.9x | -25.9x | 8.2x |
| Fri, 16 Aug 2024 | US$870.9b | US$113.2b | -US$36,254,285,538.64 | 22.2x | -24x | 7.7x |
| Sun, 14 Jul 2024 | US$1.2t | US$164.5b | -US$28,119,714,352.84 | 29.4x | -42.5x | 7.3x |
| Tue, 11 Jun 2024 | US$1.2t | US$164.5b | -US$26,797,092,425.07 | 28.1x | -43.3x | 7.1x |
| Thu, 09 May 2024 | US$1.1t | US$164.6b | -US$26,520,766,232.38 | 24.3x | -42.5x | 6.8x |
| Sat, 06 Apr 2024 | US$1.1t | US$164.4b | -US$23,433,178,577.03 | 25x | -47.8x | 6.8x |
| Mon, 04 Mar 2024 | US$1.2t | US$167.9b | -US$21,330,880,627.75 | 15.9x | -56.4x | 7.2x |
| Wed, 31 Jan 2024 | US$1.4t | US$204.7b | -US$22,654,596,727.00 | 17.8x | -63.8x | 7.1x |
| Fri, 29 Dec 2023 | US$1.4t | US$204.9b | -US$22,192,805,164.00 | 19.9x | -62.8x | 6.8x |
| Sun, 26 Nov 2023 | US$1.2t | US$204.8b | -US$22,013,452,568.00 | 18.6x | -55.7x | 6x |
| Tue, 24 Oct 2023 | US$1.2t | US$207.5b | -US$13,040,981,709.00 | 16.2x | -93x | 5.8x |
| Thu, 21 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,934,249.00 | 16.5x | -99.1x | 6.1x |
| Sat, 19 Aug 2023 | US$1.3t | US$207.6b | -US$12,299,327,844.00 | 17.4x | -102.8x | 6.1x |
| Mon, 17 Jul 2023 | US$1.1t | US$186.7b | -US$15,968,283,125.00 | 12.9x | -71.1x | 6.1x |
| Wed, 14 Jun 2023 | US$1.2t | US$186.1b | -US$15,943,311,093.00 | 11.8x | -73x | 6.3x |
| Fri, 12 May 2023 | US$1.2t | US$191.8b | -US$11,762,653,395.00 | 14.4x | -98.3x | 6x |
| Sun, 09 Apr 2023 | US$1.2t | US$216.8b | -US$5,729,497,835.00 | 14x | -203x | 5.4x |
| Tue, 07 Mar 2023 | US$1.1t | US$199.1b | -US$4,903,297,889.00 | 16x | -233.9x | 5.8x |
| Thu, 02 Feb 2023 | US$1.2t | US$204.0b | US$1.9b | 15.1x | 622.3x | 5.7x |
| Sat, 31 Dec 2022 | US$1.1t | US$203.5b | US$1.7b | 14.3x | 663.2x | 5.6x |
| Mon, 28 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 845.5x | 5.6x |
| Wed, 26 Oct 2022 | US$1.1t | US$206.5b | US$5.5b | 16.4x | 198.7x | 5.3x |
| Fri, 23 Sep 2022 | US$1.0t | US$206.2b | US$5.7b | 14.1x | 180.9x | 5x |
| Sun, 21 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
| Tue, 19 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Thu, 16 Jun 2022 | US$937.2b | US$212.0b | US$10.9b | 15.1x | 86.2x | 4.4x |
| Sat, 14 May 2022 | US$993.8b | US$212.0b | US$10.6b | 14.4x | 93.7x | 4.7x |
Price to Earnings Ratio
93.7x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 10% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.85% | |
| Healthcare | -4.05% | |
| Biotech | -6.26% | |
| Biotech | -6.26% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$269.81 | 4.9% +US$1.9b | 74.8% | PS15x | |
| EXAS Exact Sciences | US$53.99 | 20.5% +US$1.7b | -12.1% | PS3.6x | |
| NBIX Neurocrine Biosciences | US$118.92 | 10.9% +US$1.2b | -16.9% | PE38.5x | |
| BPMC Blueprint Medicines | US$99.16 | 12.1% +US$690.3m | -8.7% | PS11.4x | |
| SMMT Summit Therapeutics | US$24.20 | 2.5% +US$548.5m | 355.7% | PB52.2x |
